DNA Nanoparticles Are Safe and Nontoxic in Non-human Primate Eyes

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2018 Mar 23

PMID 29563793

Citations 16

Authors

Ryan A Kelley

Shannon M Conley

Rasha Makkia

Jamie N Watson

Zongchao Han

Mark J Cooper

Muna I Naash

Affiliations

Soon will be listed here.

Abstract

Introduction: DNA nanoparticles (NPs) comprising polylysine conjugated to polyethylene glycol efficiently target murine photoreceptors and the retinal pigment epithelium (RPE) and lead to long-term phenotypic improvement in models of retinal degeneration. Advancing this technology requires testing in a large animal model, particularly with regard to safety. So, herein we evaluate NPs in non-human primates (baboon).

Methods And Results: NPs with plasmids carrying GFP and a ubiquitous, RPE-specific, or photoreceptor-specific promoter were delivered by either subretinal or intravitreal injection. We detected GFP message and protein in the retina/RPE from eyes dosed with NPs carrying ubiquitously expressed and RPE-specific vectors, and GFP message in eyes injected with NPs carrying photoreceptor-specific vectors. Importantly, we observed NP DNA in the retina/RPE following intravitreal injection, indicating the inner limiting membrane does not prevent NP diffusion into the outer retina. We did not observe any adverse events in any baboon, and there were no NP-associated changes in retinal function. Furthermore, no systemic or local inflammatory reaction to the vectors/injections was observed, and no NP DNA was found outside the eye.

Conclusion: Taken together with the well-established rodent safety and efficacy data, these findings suggest that DNA NPs may be a safe and potentially clinically viable nonviral ocular therapy platform for retinal diseases.

Citing Articles

Non-viral gene therapy for Leber's congenital amaurosis: progress and possibilities.

Abdulsalam L, Mordecai J, Ahmad I Nanomedicine (Lond). 2024; 20(3):291-304.

PMID: 39707712 PMC: 11792828. DOI: 10.1080/17435889.2024.2443387.

In Silico CRISPR-Cas-Mediated Base Editing Strategies for Early-Onset, Severe Cone-Rod Retinal Degeneration in Three Patients, including the Novel Variant c.2833G>A.

Shamsnajafabadi H, Kaukonen M, Bellingrath J, MacLaren R, Cehajic-Kapetanovic J Genes (Basel). 2024; 15(5).

PMID: 38790254 PMC: 11121323. DOI: 10.3390/genes15050625.

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.

Krishnan A, Callanan D, Sendra V, Lad A, Christian S, Earla R Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675441 PMC: 11054942. DOI: 10.3390/ph17040481.

Next generation therapeutics for retinal neurodegenerative diseases.

Appell M, Pejavar J, Pasupathy A, Rompicharla S, Abbasi S, Malmberg K J Control Release. 2024; 367:708-736.

PMID: 38295996 PMC: 10960710. DOI: 10.1016/j.jconrel.2024.01.063.

Animal Models in Eye Research: Focus on Corneal Pathologies.

Loiseau A, Raiche-Marcoux G, Maranda C, Bertrand N, Boisselier E Int J Mol Sci. 2023; 24(23).

PMID: 38068983 PMC: 10706114. DOI: 10.3390/ijms242316661.

References

Murthy K, Salas M, Carey K, Patterson J . Baboon as a nonhuman primate model for vaccine studies. Vaccine. 2005; 24(21):4622-4. DOI: 10.1016/j.vaccine.2005.08.047. View

Conley S, Naash M . Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010; 29(5):376-97. PMC: 2907107. DOI: 10.1016/j.preteyeres.2010.04.004. View

Han Z, Banworth M, Makkia R, Conley S, Al-Ubaidi M, Cooper M . Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J. 2015; 29(6):2535-44. PMC: 4447225. DOI: 10.1096/fj.15-270363. View

Dalkara D, Kolstad K, Caporale N, Visel M, Klimczak R, Schaffer D . Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009; 17(12):2096-102. PMC: 2814392. DOI: 10.1038/mt.2009.181. View

Ziady A, Gedeon C, Muhammad O, Stillwell V, Oette S, Fink T . Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther. 2003; 8(6):948-56. DOI: 10.1016/j.ymthe.2003.09.002. View

Lapuerta P, Schein S . A four-surface schematic eye of macaque monkey obtained by an optical method. Vision Res. 1995; 35(16):2245-54. DOI: 10.1016/0042-6989(94)00320-l. View

Dudus L, Anand V, Acland G, Chen S, Wilson J, Fisher K . Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. 1999; 39(15):2545-53. DOI: 10.1016/s0042-6989(98)00308-3. View

Kim H, Robinson S, Csaky K . Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res. 2008; 26(2):329-37. DOI: 10.1007/s11095-008-9745-6. View

Chen X, Shank S, Davis P, Ziady A . Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid. Mol Ther. 2010; 19(1):93-102. PMC: 3017445. DOI: 10.1038/mt.2010.214. View

10.

Ziady A, Gedeon C, Miller T, Quan W, Payne J, Hyatt S . Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther. 2003; 8(6):936-47. DOI: 10.1016/j.ymthe.2003.07.007. View

11.

Cai X, Nash Z, Conley S, Fliesler S, Cooper M, Naash M . A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One. 2009; 4(4):e5290. PMC: 2669177. DOI: 10.1371/journal.pone.0005290. View

12.

Han Z, Conley S, Makkia R, Guo J, Cooper M, Naash M . Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery. PLoS One. 2012; 7(12):e52189. PMC: 3525534. DOI: 10.1371/journal.pone.0052189. View

13.

Fink T, Klepcyk P, Oette S, Gedeon C, Hyatt S, Kowalczyk T . Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 2006; 13(13):1048-51. DOI: 10.1038/sj.gt.3302761. View

14.

Han Z, Koirala A, Makkia R, Cooper M, Naash M . Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity. Nanomedicine (Lond). 2012; 7(4):521-39. PMC: 3404893. DOI: 10.2217/nnm.11.158. View

15.

Kevany B, Palczewski K . Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda). 2010; 25(1):8-15. PMC: 2839896. DOI: 10.1152/physiol.00038.2009. View

16.

Farjo R, Skaggs J, Quiambao A, Cooper M, Naash M . Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One. 2006; 1:e38. PMC: 1762345. DOI: 10.1371/journal.pone.0000038. View

17.

Rhee J, Pirity M, Lackan C, Long J, Kondoh G, Takeda J . In vivo imaging and differential localization of lipid-modified GFP-variant fusions in embryonic stem cells and mice. Genesis. 2006; 44(4):202-18. PMC: 2887760. DOI: 10.1002/dvg.20203. View

18.

Han Z, Conley S, Makkia R, Cooper M, Naash M . DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012; 122(9):3221-6. PMC: 3428101. DOI: 10.1172/JCI64833. View

19.

Ding X, Quiambao A, Fitzgerald J, Cooper M, Conley S, Naash M . Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One. 2009; 4(10):e7410. PMC: 2756629. DOI: 10.1371/journal.pone.0007410. View

20.

Farjo R, Peterson W, Naash M . Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci. 2008; 49(2):511-21. PMC: 2792233. DOI: 10.1167/iovs.07-1013. View